ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML)

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510717-15-00

Acronym

2282

Enrollment

Registered

2024-02-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Brief summary

clinical response: - CR = complete remission (when all of the following: < 5% blasts in the bone marrow, no Auer rods, no extramedullary disease, neutrophils >1000/μl and transfusion independent). - CRi = morphologic complete remission with incomplete blood count recovery - CRp = CR with incomplete platelet recovery - MLFS = morphologic leukemia free state not meeting criteria for CR, CRi or CRp - PR = Partial remission (decrease of 50% of the blas

Detailed description

To assess the safety of treatment with a combination of venetoclax and 6-mercaptopurine in patients with AML

Interventions

DRUGMERCAPTOPURINE

DRUGVENETOCLAX

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
clinical response: - CR = complete remission (when all of the following: < 5% blasts in the bone marrow, no Auer rods, no extramedullary disease, neutrophils >1000/μl and transfusion independent). - CRi = morphologic complete remission with incomplete blood count recovery - CRp = CR with incomplete platelet recovery - MLFS = morphologic leukemia free state not meeting criteria for CR, CRi or CRp - PR = Partial remission (decrease of 50% of the blas	—

Measure

Time frame

—

Secondary

Measure	Time frame
To assess the safety of treatment with a combination of venetoclax and 6-mercaptopurine in patients with AML	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026